Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

nt; Favrille's ability to obtain additional financing to support its operations; and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. In addition, conclusions regarding the safety and efficacy of Favrille's product candidates cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

FAVRILLE, INC.

(a development stage company)

BALANCE SHEETS

(in thousands, except share and per share data)

December 31,

2007 2006

(unaudited)

Assets

Current assets:

Cash and cash equivalents $26,362 $14,249

Short-term investments 3,577 28,160

Other current assets 806 850

Total current assets 30,745 43,259

Property and equipment, net 33,293 25,071

Restricted cash 3,451 3,451

Other assets 466 508

Total assets $67,955 $72,289

Liabilities and stockholders' equity

Current liabilities:

Accounts payable and accrued liabilities $3,551 $6,779

Current
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...Newswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (...n the development of compounds for the treatment o...unced that it has completed the last patient visit.... ,, The FDG-PET trial enrolled 52 patients an...da including Massachusetts General Hospital, Mount...
(Date:12/3/2009)...RNewswire-FirstCall/ -- Inverness Medical Innovati...ing individuals to take charge of their health at ...ealth management, has declared a dividend of $3.00...referred Stock ( IMA-PB). The dividend will be pai...re equal to the quotient of (a) $3.00 divided by (...
(Date:12/2/2009)...RNewswire-FirstCall/ -- Martek Biosciences Corpora...nds to release the results of its fourth quarter a...ximately 4:00 p.m. Eastern Time (ET). Following t...conference call to discuss these results with inve...all live via webcast by visiting Martek,s web site...
(Date:12/2/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue: ,, Carbondioxide Incubators - A Global M...com/p0164368/Carbondioxide-Incubators---A-Global-M...most critical equipment used in microbiology, gene... providing a controlled environment to grow and st...
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
...an Technology and Global Business Potential, SOUT... a,leading algal biotechnology company, today anno... of the GoingGreen 100 Top Private Companies for,2...s compiled by the,AlwaysOn editorial panel. In ord...panies had to be peer-nominated, with AlwaysOn rec...
...ation,s obesity crisis by addressing gen...SAN DIEGO, Sept. 11 Salugen, Inc., a personalized... of GenoTrim, a DNA-based,nutritional solution for...,weight through both standard weight reduction str...essful for the 58 million overweight,individuals i...
...11 /PRNewswire-FirstCall/ - MIGENIX,Inc. (TSX: MGI... for,infectious diseases, reports financial result...update on its programs. UPDATE ON DRUG DEVELOPMEN...X-226; topical cationic peptide;,prevention of cat...dy is in,progress in the United States under a Spe...
Other Biology Technology:Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner 2Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner 3Salugen Announces the U.S. Launch of GenoTrim - a DNA Customized Nutritional Solution for Weight Management 2Salugen Announces the U.S. Launch of GenoTrim - a DNA Customized Nutritional Solution for Weight Management 3MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 2MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 3MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 4MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 5MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 6MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 7MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 8MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 9MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 10MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 11MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 12MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 13MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 14MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results 15
(Date:12/3/2009)..., , Spanish researchers have measured CO2 levels ... atmosphere) over a sparsely inhabited rural area ...of their kind in the Iberian Peninsula, show that ...005. , Over recent years, physicists and meteoro...dioxide (CO2) levels, and how these have evolved i...
(Date:12/3/2009)..., The 30-year record low in Antarctic snowmelt th...likely due to concurrent strong positive phases fo...n Oscillation) and SAM (Southern Hemisphere Annula... Professor of Earth & Atmospheric Sciences at The ... who is also on the doctoral faculty at the CUNY G...
(Date:12/2/2009)..., , PHILADELPHIA New study results strengthen th... long period of time have an increased risk for de...or other risk factors. , "This provides one mor...ble," said senior author Michael J. Thun, M.D., M....eillance research at the American Cancer Society. ...
Breaking Biology News(10 mins):CO2 levels rising in troposphere over rural areas 2CCNY professor foresees rising Antarctic snowmelt 2Cigarette smoking increases colorectal cancer risk 2US Government Places 6 1 Million USD Orders Related to Precise Match on Card 28TM 29 for Cyber Security Programs 9217 1US Government Places 6 1 Million USD Orders Related to Precise Match on Card 28TM 29 for Cyber Security Programs 9217 2Type of Knee Surgery Makes Difference in Football Career 51400 1Type of Knee Surgery Makes Difference in Football Career 51400 2Obama 3A Too Many Still Die from Diseases That Shouldnt Kill Them 51397 1Obama 3A Too Many Still Die from Diseases That Shouldnt Kill Them 51397 2
...genome or the egg genome? , Researchers have answ...nomic question: Which of the thousands of long str...rst? And which are the duplicates? , The answers,...7, 2007, provide the first evolutionary history of...tly responsible for both disease and recent geneti...
... Capecchi, Ph.D., distinguished professor of human...ccles Institute of Human Genetics and a Howard Hug...07 Nobel Prize in Physiology or Medicine. , The a...embly at the Karolinska Institute, in Stockholm, S...evelopment of knockout mice technology, a gene-tar...
...nati (UC) radiologists have developed a new techni... diagnosis of venous diseases. , Multi-detector c... used to create three-dimensional images of arteri... from the heart and distribute blood throughout th...o the heart, are more difficult to accurately imag...
Other Biology News:Which came first, the chicken genome or the egg genome? 2Which came first, the chicken genome or the egg genome? 3Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine 2Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine 3New thoracic imaging approach can pinpoint underlying venous problems 2
Goat Anti-Human PLUNC Polyclonal Antibody, Biotin Conjugated from R&D Systems
Mouse Anti-Human RXR beta / NR2B2 Monoclonal Antibody, Unconjugated, Clone H7341 from R&D Systems
Rabbit Anti-GRASP1 Polyclonal Antibody, Unconjugated from Abcam
Porcine Galanin , 3-[125I]iodotyrosyl26 Conjugated/Tagged from GE Healthcare, formerly Amersham Biosciences
Biology Products: